PSAT250 Thyroid Carcinoma – the Diagnostic Value and Management: the Single-Centre Real-World Retrospective Study 2019–2021 (Part I)

BACKGROUND: Ultrasound imaging and fine-needle aspiration (FNA) is the mainstay in evaluating thyroid nodules. There is a substantial lack of recent data from Latvia on thyroid carcinoma. AIM: This study aimed to determine effectiveness in a particular service medical tool called Green Corridor. We collected the data on the prevalence of thyroid carcinoma by FNA and after surgical intervention and compared both data since the malignant result in the FNA is an indication for surgery. METHODS: We provided the single-centre real-world retrospective observational study (2019–2021). We analysed patients sent to physicians along the Green Corridor with code Z03.173 (ICD-10) in Riga East Clinical University Hospital. After surgical interventions, we collected FNA data, treatment types, thyroid cancer types, comorbidities, and thyroid antibodies. The data indicated the number of malignancies cytologically, starting from Bethesda III (atypia of undetermined significance or follicular lesion of uncertain significance) and histologically. We compared the two methods. We analysed the efficiency of the Green Corridor. The statistical analysis was conducted using IBM SPSS. RESULTS: We manually analysed the medical records of 563 patients for three years. Thyroid cancer was confirmed in 153 patients (27.2%); women were 123 patients (80.4%). The average age was 53.5 ± 14.3 SD years. 147 patients had surgical intervention (total thyroidectomy (91.5%) or hemithyroidectomy) and confirmed thyroid cancer histologically (mainly papillary carcinomas – 82 pts (59.4%)). Four patients (2.6%) had radiation therapy, two patients (1.3%) had palliative care due to an inoperable condition. FNA results of malignancy coincided with the histological analysis in 114 patients (77%). In 84 (73.7%) patients, FNA results of malignancy types coincided with the histological analysis. CONCLUSION: The fine-needle aspiration biopsy is the gold standard for malignancy diagnostic in thyroid cancer and has proven its high diagnostic value in combination with cost-effectiveness and minimal invasiveness. According to the Green Corridor, the distribution of patients has proven its effectiveness, taking into account its percentage as far as the disease is histologically confirmed. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.